Alzheimer’s Drugs Market Report Up to 2031

Visiongain has published a new report on Alzheimer’s Drugs Market Report to 2031: Forecasts by Drugs (Donepezil, Rivastigmine, Galantamine, and Memantine), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce) PLUS COVID-19 Recovery Scenarios.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/alzheimers-drugs-market/#download_sampe_div

COVID-19 Impact on Alzheimer’s Drugs Market
The COVID-19 pandemic has deleteriously affected all the countries and industries. Similarly, the Alzheimer’s drug market is anticipated to take a hit. The target industry is now facing challenges to manage the interrupted demand and supply of components. Also, unpredictable and disturbing supply chain activities and the unavailability of human resources are anticipated to impact the target industry growth. In contrast, the rising research & development activities for developing novel treatments against COVID-19 is creating a lucrative opportunity for the companies. Hence, the overall COVID-19 impact is expected to continue to moderate for the global key players operating in the industry.

Market Drivers

Growing Incidence of Alzheimer’s Disease
The growing occurrence and prevalence of Alzheimer’s disease globally are anticipated to propel the growth of Alzheimer’s drug market. Growing age and the elderly population are at a high risk to develop Alzheimer's disease, which raises the disease occurrence and offers growth opportunities for Alzheimer’s drug market. According to World Population Prospects (WPP) published in 2017 by the United Nations, around 962 million people over age 60, which is estimated for 13% of the worldwide population is anticipated to reach approximately 1.4 billion by 2030, rising at an annual rate of 3%.

Currently, Europe has the highest old population accounting for 25% of the population, the Asia Pacific had an elderly people of 547 million people and it is likely to reach around 900 million by 2025, therefore these regions have potential opportunities for the target market. For the case, India has over 1 million cases of Alzheimer’s disease yearly. The vigorous healthcare infrastructure and rising healthcare spending in the region and positions it as a key market for Alzheimer’s disease.

A Large Number of Undiagnosed People and Revised Diagnostic Guidelines
People affected by the initial stages of Alzheimer’s disease with dementia do not have suitable access to the diagnostic center to identify and treat the disease. According to the World Alzheimer Report, only about 50% of people suffering from Alzheimer’s disease undergo diagnosis. The degree of underdiagnoses is about 10% in developing economies, hence, it is likely to boost the Alzheimer’s drug market growth in the forecasted period. Presently, there is no healing treatment existing for Alzheimer’s disease. Though, drugs for Alzheimer’s treatment are in pipeline, which is anticipated to introduce in the coming years, which in turn, is expected to attain a significant growth rate to the target industry during the forecast period.

Get Detailed TOC @ https://www.visiongain.com/report/alzheimers-drugs-market/#download_sampe_div

Market Opportunities

Developments in Techniques for Diagnosis expand Outlook of Target Industry
The developments in techniques for diagnosis, especially by using state-of-the-art PET neuroimaging and cerebrospinal fluid biomarkers have extended the growth projections of the Alzheimer’s drug market. The huge health burden that Alzheimer's disease stances have also reserved the drug pipeline prepared with prospects for the companies, particularly in emerging countries. Their governments to decrease the health burden of Alzheimer's disease have progressively sustained this. Many companies in developed countries such as the U.S. and Europe have been targeting neurodegenerative trails to develop novel therapies against dementia.

Competitive Landscape
Key players operating in the global Alzheimer’s Drugs market are Pfizer, Inc., Lundbeck A/S, Novartis International AG, Hoffman-La Roche Ltd., Janssen Pharmaceutical, TauRx Pharmaceuticals Ltd, Eisai Co. Ltd., and Teva Pharmaceuticals Industries Ltd., VTV Therapeutics, Eli Lilly and Company, AstraZeneca plc, and AC Immune.

The key players have adopted new product development, product launches, product approval, agreement, partnerships, and merger as its key business development strategies to tap into the global Alzheimer’s Drugs market. For instance, on 21st October 2020, Biogen Inc. received the U.S. Food and Drug Administration authorization for aducanumab - Alzheimer's drug. The company filed its application for the drugs to the other regulator bodies as well includes Europe and Japan. The company will soon launch its drug after getting international approval.

Request Customized Report as Per Your Requirements @ https://www.visiongain.com/contact/

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To access the data contained in this document please email contactus@visiongain.com

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Alzheimer’s Drugs Market and leading companies. You will find data, trends and predictions.

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: catherine.walker@visiongain.com

Catherine Walker
PR at Visiongain Inc.
Tel: + 44 0207 336 6100
USA Tel: + 1 718 682 4567
EU Tel: + 353 1 695 0006
Toll Free: 00-1-646-396-5129
Email: catherine.walker@visiongain.com
Research Insight : https://www.visiongain.com/alzheimers-drugs-market-analysis/

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

This release was published on openPR.